Letter to the Editor| Volume 52, e43-e44, June 2018

Comment on “Mild water restriction with or without urea for the longterm treatment of SIADH: Can urine osmolality help the choice?” by Decaux et al.

Published:February 02, 2018DOI:
      Dear Editor,


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Decaux G.
        • Gankam Kengne F.
        • Couturier B.
        • Musch W.
        • Soupart A.
        • Vandergheynst F.
        Mild water restriction with or without urea for the longterm treatment of SIADH: can urine osmolality help the choice?.
        Eur J Intern Med. 2017;
        • Castello L.M.
        • Baldrighi M.
        • Settanni F.
        • Avanzi G.C.
        • Bartoli E.
        Quantitative approach for the treatment of hypovolemic hyponatremia in the emergency department.
        J Anat Physiol. 2017; 2: 1012
        • Morgenthaler N.G.
        • Struck J.
        • Jochberger S.
        • Dünser M.W.
        Copeptin: clinical use of a new biomarker.
        Trends Endocrinol Metab. 2008; 19: 43-49
        • Vetrone F.
        • Santarelli S.
        • Russo V.
        • et al.
        Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea.
        Clin Chem Lab Med. 2014; 52: 1457-1464
        • Winther J.A.
        • Brynildsen J.
        • Høiseth A.D.
        • et al.
        Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study.
        Respir Res. 2017; 18: 184
        • Yan J.J.
        • Lu Y.
        • Kuai Z.P.
        • Yong Y.H.
        Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis.
        J Cell Mol Med. 2017; 21: 1815-1825
        • Dres M.
        • Hausfater P.
        • Foissac F.
        • et al.
        Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.
        Int J Chron Obstruct Pulmon Dis. 2017; 12: 1047-1056
        • Nigro N.
        • Winzeler B.
        • Suter-Widmer I.
        • et al.
        Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The co-MED Study'.
        Clin Endocrinol (Oxf). 2017; 86: 456-462
        • Winzeler B.
        • Lengsfeld S.
        • Nigro N.
        • et al.
        Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresis.
        J Intern Med. 2016; 280: 609-617
        • Castello L.M.
        • Baldrighi M.
        • Panizza A.
        • Bartoli E.
        • Avanzi G.C.
        Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department.
        Intern Emerg Med. 2017; 12: 993-1001